| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
17β-HSD10-IN-1 specifically targets 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10), a mitochondrial enzyme involved in the metabolism of sex steroids and the oxidation of neurotoxic amyloid-beta peptides. It is a potent inhibitor of this enzyme and has been designed to protect neurons from amyloid-beta toxicity.
|
|---|---|
| ln Vitro |
In vitro, 17β-HSD10-IN-1 inhibits 17β-HSD10 activity. It demonstrates high potency and selectivity, with no additional effects on mitochondrial off-targets. The compound shows no cytotoxic or neurotoxic effects in cell-based assays, indicating a favorable safety profile for a CNS-targeted compound.
|
| ln Vivo |
In vivo, 17β-HSD10-IN-1 is orally active and blood-brain permeable. It has been investigated in preclinical models of Alzheimer's disease. By inhibiting 17β-HSD10, the compound may reduce amyloid-beta toxicity and protect neurons. Its oral bioavailability and brain penetration support its use in chronic dosing studies.
|
| Enzyme Assay |
The inhibitory activity of 17β-HSD10-IN-1 against 17β-HSD10 is assessed using enzyme activity assays. Recombinant human 17β-HSD10 enzyme is incubated with the substrate (e.g., estradiol or androstenedione) and NAD⁺/NADH cofactor in the presence of varying concentrations of the compound. The conversion of substrate to product is monitored spectrophotometrically or by HPLC. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
Cellular assays for 17β-HSD10-IN-1 involve treating neuronal cell lines with the compound and assessing 17β-HSD10 activity and amyloid-beta toxicity. The compound's ability to protect neurons from amyloid-beta-induced cell death is evaluated using viability assays (MTT, LDH release). Mitochondrial function is assessed by measuring ATP levels and mitochondrial membrane potential. Cytotoxicity is evaluated to confirm the lack of neurotoxic effects.
|
| Animal Protocol |
In vivo studies of 17β-HSD10-IN-1 are conducted in transgenic mouse models of Alzheimer's disease. The compound is administered orally. Cognitive function is assessed using behavioral tests such as the Morris water maze and novel object recognition. Amyloid-beta pathology, tau phosphorylation, and neuroinflammation are evaluated in brain tissue. Pharmacodynamic markers of 17β-HSD10 inhibition are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 17β-HSD10-IN-1 (molecular weight 376.82) are evaluated in rodents following oral administration. The compound's blood-brain permeability is assessed by measuring brain-to-plasma concentration ratios. Plasma and brain concentrations are measured using LC-MS/MS to determine key PK parameters including oral bioavailability, half-life, and brain penetration.
|
| Toxicity/Toxicokinetics |
17β-HSD10-IN-1 shows no cytotoxic or neurotoxic effects and does not result in additional effects for mitochondrial off-targets. This suggests a favorable safety profile for a CNS-targeted compound. The compound is intended for research use only and is not approved for clinical use.
|
| References | |
| Additional Infomation |
17β-HSD10-IN-1 is a research tool for studying the role of 17β-HSD10 in Alzheimer's disease. 17β-HSD10 is a mitochondrial enzyme that plays a role in the metabolism of neurotoxic amyloid-beta peptides and sex steroids. Inhibition of 17β-HSD10 has been proposed as a therapeutic strategy for Alzheimer's disease. This compound provides a valuable tool for validating 17β-HSD10 as a therapeutic target.
|
| Molecular Formula |
C16H13CLN4O3S
|
|---|---|
| Molecular Weight |
376.817420721054
|
| Exact Mass |
376.04
|
| Elemental Analysis |
C, 51.00; H, 3.48; Cl, 9.41; N, 14.87; O, 12.74; S, 8.51
|
| CAS # |
2316765-78-1
|
| PubChem CID |
168476163
|
| Appearance |
Pale purple to purple solid powder
|
| LogP |
2.7
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
25
|
| Complexity |
512
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1=C(C=CC(=C1)NC(NC1=NC2C=CC(=CC=2S1)NC(C)=O)=O)O
|
| InChi Key |
JLNKZAOURVXTHS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H13ClN4O3S/c1-8(22)18-10-2-4-12-14(7-10)25-16(20-12)21-15(24)19-9-3-5-13(23)11(17)6-9/h2-7,23H,1H3,(H,18,22)(H2,19,20,21,24)
|
| Chemical Name |
N-(2-(3-(3-chloro-4-hydroxyphenyl)ureido)benzo[d]thiazol-6-yl)acetamide
|
| Synonyms |
17β-HSD10-IN-1; 17β-HSD10-IN 1; 17β HSD10-IN-1; 17β-HSD10 IN-1
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6538 mL | 13.2689 mL | 26.5379 mL | |
| 5 mM | 0.5308 mL | 2.6538 mL | 5.3076 mL | |
| 10 mM | 0.2654 mL | 1.3269 mL | 2.6538 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
